10 / 16
Escenario Avanzado
Fase III - CT-P6
Im YH, J Clin Oncol 31, 2013 (suppl; abstr 629).
ITRC
Investigator
CT-P6 + Paclitaxel
(n = 244)
Trastuzumab + Pac
(n = 231)
CT-P6 + Paclitaxel
(n = 244)
Trastuzumab + Pac
(n = 231)
Complete response
9 (3.7%)
4 (1.7%)
12 (4.9%)
6 (2.6%)
Partial response
129 (52.9%)
139 (60.2%)
146 (59.8%)
152 (65.8%)
Stable disease
49 (20.1%)
38 (16.5%)
61 (25.0%)
56 (24.2%)
Overall response rate
138 (56.6%)
143 (61.9%)
158 (64.8%)
158 (68.4%)
Difference, % [95% CI]
5.4 [-14.3, 3.6]
3.6 [-12.6, 5.4]